WHO Clinical operations for COVID-19: Therapeutics and oxygen

Member state briefing, 17 June 2021 Janet V Diaz, MD Lead, Clinical management COVID-19 response WHO, Health Emergencies Programme





Clinical management during pandemics


Prevention remains key to stopping transmission

Once on rapid increase in curve, health systems can become quickly overwhelmed






Comprehensive, multi-disciplinary, holistic: from triage to recovery




HEALTH EMERGENCIES programme

WHO Living guidelines for COVID-19: Also available on MAGICapp, BMJ

https://www.who.int/publicati ons/i/item/WHO-2019-nCoVtherapeutics-2021.1



WHO care bundles for home care and health facility: evidence-based interventions done together to improve outcomes



WHO COVID-19 CLINICAL CARE BUNDLE For patients presenting at a health care facility



To be performed, **as soon as possible**, on presentation of a patient at a health care facility



Apply appropriate IPC: wear mask, gloves, gown and eye protection



Check vital signs, including measure of respiratory rate and pulse oximetry



Provide oxygen support, if $SpO_3 < 90\%$ on room air or emergency signs*



Administer dexamethasone, if patient has severe disease**



Administer medicine to prevent thrombosis, in adolescents and adults, when not contraindicated, on day of admission






WHO Living guidelines for COVID-19: http: Next update August 2021

https://www.who.int/publications/i/ite m/WHO-2019-nCoV-clinical-2021-1

New recommendations on the way anticipate publication in August 2021:

. MISC recommendations: GDG meeting 24 June 2021.



- Non-invasive ventilation (NIV) and high flow nasal oxygen (HFNO) for severe and critical COVID-19.
 - GDG meeting late July 2021.
 - Current recommendation to use NIV or HFNO for some case of critical COVID-19 (i.e. mild ARDS) with caution.

3. New systematic review data on:

- 1. Co-infections: i.e. mucormycosis—main message: better diagnosis and management of DM—avoid hyperglycemia and rationale use of corticosteroids (low dose, short course, severe/critical COVID-19)
- 2. Pregnancy and COVID
- 3. Children and COVID
- 4. HIV and COVID





WHO Living guidelines for COVID-19: Next update 30 June 2021

https://www.who.int/publicati ons/i/item/WHO-2019-nCoVtherapeutics-2021.1

 Therapeutics and COVID-19

 LIVING GUIDELINE

 MARCH 2021

New recommendation to be published 30 June 2021 (Draft) Strong recommendation for IL 6 receptor blockers (Tocilizumab, sarilumab) for severe and critical COVID-19. Corticosteroids have previously been strongly recommended in patients with severe and critical COVID-19, and we recommend patients meeting these severity criteria should now receive both corticosteroids and IL-6 receptor blockers..

In pipeline for GDG June and July:

REGN-COV2, colchicine, baricitinib, anticoagulants (full dose), cPlasma


Monitoring studies on the following closely:

Molnupiravir, GSK-VIR 7832 (sotronib), bamlanivimab





WHO Oxygen access initiative





COVID-19 Respiratory support research: O2CoV2 observational study: JUST LAUNCHED EOI

- Full title: Oxygen requirements and approaches to respiratory support in patients with COVID-19 in low- and middle-income countries
- Targeting 4 countries per WHO region; 2 paired sites per country
- Prospective cohort study to understand patient level use of oxygen and respiratory support devices
- Expressions of Interest form available online and via QR code, open until 9 July 2021 Please share with relevant networks

https://www.who.int/initiatives/oxygen-access-scale-up

covidrespstudy@who.int

'Id Health





Oxygen access scale-up





wing Adsorption	Technical specifications for (PSA) Oxygen Plants Interim guidance 8 June 2020	Pressure Swing Adsorption
An expanse details as water, of a second se	<text><text><list-item><list-item><list-item><section-header><text><text><text></text></text></text></section-header></list-item></list-item></list-item></text></text>	<text><text><section-header><text><text><text><text><text></text></text></text></text></text></section-header></text></text>

THE **NEED-GAP** IS UNDERSTOOD AS THE FORECASTED NEED MINUS THE BASELINE SUPPLY CAPACITY

What are the outstanding need-gaps?

- Oxygen sources
- Distribution systems



- Delivery equipment
- Consumables
- Spare parts
- Training
 - Maintenance, service agreements
- Power generation

Funding

1. Coordination and expertise: **Biomedical experts + OSL + clinical teams** working together: forecast needs, needs-gap assessment (ESFT), develop contextualized solution and then procurement, installation, and commissioning. Work with partners on ground (mapping available).

- 2. Readiness is key: what is the surge plan?
 - Liquid bulk: map suppliers in country and region, estimate
 - <u>PSA procurement</u>: standardized RFP for procurements available
 - <u>PSA repair:</u> WHO launched EOI for entities that do repairs and maintenance—4 submissions now being evaluated
 - <u>Cylinders:</u> local suppliers with local QA (tech support can be provided)





Global Supply Chain Dashboard





Weekly Comparison from Supply Chain Dash – O2 Conc. focus







WHO Biomed Procurement - Cumulative

Regional Cumulative Breakdown

ltem 🔟	AFRO	EMRO	EURO	PAHO	SEARO	WPRO	Grand Total
BIPAP	220	423	152	24	73	38	930
Bubble humidifier	150		50				200
Flow splitter	154	60				2	216
HFNC	214	279	290		566	70	1,419
HMEF	50		2,000				2,050
Nasal oxygen cannula - adult	91,061	39,300	90,890	6,480	5,220	31,680	264,631
Nasal oxygen cannula - paediatric	65,685	33,600	7,340	6,480	5,220	31,680	150,005
Oxygen conc 10L	294	337	1,178			184	1,993
Oxygen conc 8L	3,670	3,374	3,369	639	4,810	2,329	18,191
Oxygen mask - adult	16,471	18,300	103,708		70,000	8,120	216,599
Oxygen mask - paediatric	8,170	520	6,100		9,500	8,060	32,350
Oxygen plant	2		1				3
Patient monitor	1,354	2,155	1,467	36	106	306	5,424
Pulse oximeter	7,635	2,858	5,572	118	5,770	1,854	23,807
Spare parts, O2 conc.	2,380	1,501	221	324	4,061	1,109	9,596
Thermo infrared	8,864	2,199	1,760		710	700	14,233
Ventilation bag	22	115	350			100	587
Ventilator	45	14	2				61
Ventilator - type 1	234	5	128		13	198	578
Ventilator - type 2	137	27	10		8		182
Venturi mask - adult	24,761	10,941	97,835	1,620	24,305	13,745	173,207
Venturi mask - paediatric	18,235	9,283	6,785	1,620	13,905	13,645	63,473

O2 concentrators:

- 20,184 units delivered
- **8,000** units in preparation

WHO represent 46%


Total Cost \$67,726,469





Biomedical Essential Supplies update

Average lead-time from purchase order placed to item delivered (IN DAYS)



136

Biomedical items/asset market scarcity:

- O2 concentrator: lead time X 4 (3 months)
- High demand on accessories and consumables
- Other assets (ventilator, Bibap) remain accessible (3 to 4 weeks lead time)
- Transport/logistics remain a serious concern (average \$X2 up to X4)

Global supply:

- Other system are in place, but demand on WHO
- Portal still up and running
- Catalogue is being updated to best match the therapeutic approach

Forecast and supply data

- ESFT new version online V4.1. Imperial college data. More than 400 persons
- Global supply data dashboard





Thank you



